Advertisement
Advertisement
U.S. Markets open in 2 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1210-0.0349 (-22.39%)
At close: 03:59PM EST
Advertisement
Sign in to post a message.
  • l
    lonearnie
    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and Drug Administration (FDA), granting a Type C meeting to discuss safety and labelling requirements for obtaining marketing approval under the 505(b)(1) regulatory pathway for its QIXLEEF(TM).
  • g
    gmanwicksy
    Fire Guy, anyone who votes him in again next year needs their head examined. Great company, great science, great patents, great drug pipeline, fantastic opportunity here but #$%$ CEO. Bad timing as markets are tanking today and tomorrow. However we do need the money to get Reduvo and Enjouca and Qixleef going. Short term pain long term gain. We are going to make money, just not until we get DIN in hand and drug approvals. But yes demote Guy and lets get a real pharma CEO shall we. Congrats to shorts in this market right now.
  • L
    Lloyd
    Hi Diane,

    Can you tell us again how great of a scientist Guy is and how he’s going to lead all shareholders to riches by creating the first cannabis related drug.

    How many outstanding shares are we at now?
  • t
    thebostonangler
    Here are the headlines over the past 4 months. Yes they are raising money. That's what you do when you are doing trials and are preparing for launch... I love seeing this being sold off, it is a great opportunity to pick up some shares. It takes ice water in your veins to buy at times like this. But I've seen this go from .11 to .40 pretty quick... This is Vegas at it's best... So lay your bet down. Currently it will take shorts 3.85 days to cover... That should be fun to watch.

    December 2021
    Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units

    November 2021
    QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols

    November 2021
    Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

    October 2021
    Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

    October 2021
    REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.

    September 2021
    Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

    July 2021
    Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
  • b
    bob
    You investors are going to have a bad day, so I’m going to try and wake you up!
    The past financing took place in late May at $10,000,000, 25m shares at $.40and full warrants, 50m share dilution.
    The Reborn1 head to head trial had started May 4, Guy advised no worries with enrolees as hospital space was freeing up from covid patients, trial time 18 weeks, should wrap up end September. No news, no news, then 1 enrolee after 8 weeks but the trial needs 20!! Ask Chamberland for cuurent status of the trials in mid june and july, standard BS from TBP, oh “not for public disclosure” the FDA says it could skew results.
    BURN RATE $2,000,000/month which includes Guys full salary.
    Now here we are at Dec.1 and of course they are out of cash, and the terms “opinion” and “possibly if it works” are used instead of the “Reborn 1 is a simple head to head trial lasting 18 weeks” which is now 30 weeks in.
    Transparency is not a word to use with TBP, and the new financing is $13,000,000 with full warrants, likely never to be exercised, at a dilution of around 40%, so you’re looking at a $.13 SP on Thursday.
    This shouldn’t be allowed.
  • S
    Steven
    Wow FB Diane s acknowledging there is shadiness going on and implying that Dr Guy has possibly breached his fiduciary duty to shareholders.
  • V
    Vinny
    Head office address
    2316 St-Joseph Blvd.
    Orleans, ON Canada
    K1C 1E8

    Just type the Head Office address in Google Street View and you will realize what mistake you have made investing in TBP

    Head office address
    2316 St-Joseph Blvd.
    Orleans, ON Canada
    K1C 1E8
  • P
    Pino
    Clearly Dr Guy has a total disregard for the shareholders. Need a CEO with a business mind.
  • B
    Bill
    The lack of ethics involved in stock dilution notwithstanding, the fact the company was able to make the deal shows there is still confidence in this enterprise. It's small consolation to shareholders who've seen their investment reduced and the timelines increased dramatically, but it is what it is.
  • A
    Abel
    Disclaimer
    Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
    Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
    Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
  • L
    Lloyd
    Hi Diane,

    Remember when you took screenshots of my comments from this board and posted it to your fb page trying to call me out and saying you shouldn’t take inventing advice from a yahoo message board? Wow did you ever feel high and mighty then. Trying to shame a fellow investor who wasn’t happy with the company smh.

    I remember I had high hopes for this company. I truly believed. And then I saw a pattern with Guy and what he told investors. It all started when he said “tbp will begin to generate revenues in 2019”. Well we waited and waited and waited, no revenues happened. In fact the company sold off some of those potential revenue generating avenues for nothing to pursue…ARDS lol. Another fun Guy Chamberland rouse to lure investors into thinking this company was going to accomplish something great.

    Oh well. At least we’ll have the memories Diane.

    I hope too many people didn’t take your advice to invest in a company that only looks to serve the executive team by diluting shareholder value so they can continue to pay themselves a salary.

    I wonder if you could get Guy to explain this farce on your fb page?

    Anyways, Keep on truckin girl.
  • L
    Long-John
    So just about .20 CAD and back in the parking lot. Guy’s double pump didn’t work. He’ll try again at the start of 2022, followed by the usual dilution, when the till is empty.
  • B
    Bruce
    This just in 50 minutes ago , Guess we know why the previous ATM offering was canceled , Read...

    https://ca.finance.yahoo.com/news/tetra-bio-pharma-announces-13-220900686.html
  • J
    Janet
    Things are brewing!!
  • W
    Wow
    This is excellent news and only the tip of the iceberg. Once completely accepted it will become a bettwer option than getting opiods for all high level pain in society. Why risk the addiction and toxic nature to opiods.
  • M
    Mark
    Once din and qixleef approved, this thing will skyrocket to .50c / share.
    Bullish
  • g
    gmanwicksy
    A and C warrants selling like hotcakes now. Get yours before they are gone. See you at a $ plus soon. Gap ups coming in the future.
  • g
    gmanwicksy
    Will we get news of a pp or another bought deal? If so vote Guy out. Or will there will be more and more news and updates pushing the price above .28 .40 .75 and then calling in of warrants as prices remain above those strike prices? That would be the best plan to call in warrants as prices rise that way there is no further dilution. This should be the plan. Why else did the ATM get cancelled? Alot of money can be raised in outstanding warrant redemption.
  • r
    robert
    As previously stated, TBP is stuck in a financing cycle that typically doesn’t end well for companies.
Advertisement
Advertisement